The immunomodulatory quinoline-3-carboxamide paquinimod reverses established fibrosis in a novel mouse model for liver fibrosis

Nina Fransén Pettersson; Adnan Deronic; Julia Nilsson; Tine Hannibal; Lisbeth Hansen; Anja Schmidt-Christensen; Fredrik Ivars; Dan Holmberg

doi:10.1371/journal.pone.0203228

The immunomodulatory quinoline-3-carboxamide paquinimod reverses established fibrosis in a novel mouse model for liver fibrosis

Nina Fransén Pettersson, Adnan Deronic, Julia Nilsson, Tine Hannibal, Lisbeth Hansen, Anja Schmidt-Christensen, Fredrik Ivars, Dan Holmberg

Research output: Contribution to journal › Article › peer-review

Abstract

Quinoline-3-carboxamides (Q substances) are small molecule compounds with anti-inflammatory properties. In this study, we used one of these substances, Paquinimod, to treat a novel model for chronic liver inflammation and liver fibrosis, the NOD-Inflammation Fibrosis (N-IF) mouse. We show that treatment of N-IF mice significantly reduced inflammation and resulted in the regression of fibrosis, even when the treatment was initiated after onset of disease. The reduced disease phenotype was associated with a systemic decrease in the number and reduced activation of disease-promoting transgenic natural killer T (NKT)-II cells and their type 2-cytokine expression profile. Paquinimod treatment also led to a reduction of CD115+ Ly6Chi monocytes and CD11b+ F4/80+ CD206+ macrophages.

Original language	English
Article number	e0203228
Journal	PLoS ONE
Volume	13
Issue number	9
DOIs	https://doi.org/10.1371/journal.pone.0203228
Publication status	Published - 2018 Sept 5

Subject classification (UKÄ)

Immunology in the medical area

Access to Document

10.1371/journal.pone.0203228Licence: CC BY

1 Doctoral Thesis (compilation)

Cellular and molecular mechanisms in immune mediated hepatic fibrosis. A study of the inflammatory syndrome and fibrosis development of the NIF mouse liver.
Nilsson, J., 2020, Lund : Lund University, Faculty of Medicine. 81 p.
Research output: Thesis › Doctoral Thesis (compilation)

Open Access
File

1 Active

chronic Inflammation and fibrosis
Schmidt-Christensen, A., Nilsson, J., Holmberg, D. & Fransén Pettersson, N.
2013/08/01 → …
Project: Research

Cite this

@article{ff8147bc6d5f4753a118c3c67454dc2e,

title = "The immunomodulatory quinoline-3-carboxamide paquinimod reverses established fibrosis in a novel mouse model for liver fibrosis",

abstract = "Quinoline-3-carboxamides (Q substances) are small molecule compounds with anti-inflammatory properties. In this study, we used one of these substances, Paquinimod, to treat a novel model for chronic liver inflammation and liver fibrosis, the NOD-Inflammation Fibrosis (N-IF) mouse. We show that treatment of N-IF mice significantly reduced inflammation and resulted in the regression of fibrosis, even when the treatment was initiated after onset of disease. The reduced disease phenotype was associated with a systemic decrease in the number and reduced activation of disease-promoting transgenic natural killer T (NKT)-II cells and their type 2-cytokine expression profile. Paquinimod treatment also led to a reduction of CD115+ Ly6Chi monocytes and CD11b+ F4/80+ CD206+ macrophages.",

author = "{Frans{\'e}n Pettersson}, Nina and Adnan Deronic and Julia Nilsson and Tine Hannibal and Lisbeth Hansen and Anja Schmidt-Christensen and Fredrik Ivars and Dan Holmberg",

year = "2018",

month = sep,

day = "5",

doi = "10.1371/journal.pone.0203228",

language = "English",

volume = "13",

journal = "PLoS ONE",

issn = "1932-6203",

publisher = "Public Library of Science (PLoS)",

number = "9",

}

TY - JOUR

T1 - The immunomodulatory quinoline-3-carboxamide paquinimod reverses established fibrosis in a novel mouse model for liver fibrosis

AU - Fransén Pettersson, Nina

AU - Deronic, Adnan

AU - Nilsson, Julia

AU - Hannibal, Tine

AU - Hansen, Lisbeth

AU - Schmidt-Christensen, Anja

AU - Ivars, Fredrik

AU - Holmberg, Dan

PY - 2018/9/5

Y1 - 2018/9/5

N2 - Quinoline-3-carboxamides (Q substances) are small molecule compounds with anti-inflammatory properties. In this study, we used one of these substances, Paquinimod, to treat a novel model for chronic liver inflammation and liver fibrosis, the NOD-Inflammation Fibrosis (N-IF) mouse. We show that treatment of N-IF mice significantly reduced inflammation and resulted in the regression of fibrosis, even when the treatment was initiated after onset of disease. The reduced disease phenotype was associated with a systemic decrease in the number and reduced activation of disease-promoting transgenic natural killer T (NKT)-II cells and their type 2-cytokine expression profile. Paquinimod treatment also led to a reduction of CD115+ Ly6Chi monocytes and CD11b+ F4/80+ CD206+ macrophages.

AB - Quinoline-3-carboxamides (Q substances) are small molecule compounds with anti-inflammatory properties. In this study, we used one of these substances, Paquinimod, to treat a novel model for chronic liver inflammation and liver fibrosis, the NOD-Inflammation Fibrosis (N-IF) mouse. We show that treatment of N-IF mice significantly reduced inflammation and resulted in the regression of fibrosis, even when the treatment was initiated after onset of disease. The reduced disease phenotype was associated with a systemic decrease in the number and reduced activation of disease-promoting transgenic natural killer T (NKT)-II cells and their type 2-cytokine expression profile. Paquinimod treatment also led to a reduction of CD115+ Ly6Chi monocytes and CD11b+ F4/80+ CD206+ macrophages.

U2 - 10.1371/journal.pone.0203228

DO - 10.1371/journal.pone.0203228

M3 - Article

C2 - 30183741

SN - 1932-6203

VL - 13

JO - PLoS ONE

JF - PLoS ONE

IS - 9

M1 - e0203228

ER -

The immunomodulatory quinoline-3-carboxamide paquinimod reverses established fibrosis in a novel mouse model for liver fibrosis

Abstract

Subject classification (UKÄ)

Access to Document

Fingerprint

Research output

Cellular and molecular mechanisms in immune mediated hepatic fibrosis. A study of the inflammatory syndrome and fibrosis development of the NIF mouse liver.

Projects

chronic Inflammation and fibrosis

Cite this